TW201713641A - 經取代之喹喏啉衍生物 - Google Patents

經取代之喹喏啉衍生物 Download PDF

Info

Publication number
TW201713641A
TW201713641A TW105114781A TW105114781A TW201713641A TW 201713641 A TW201713641 A TW 201713641A TW 105114781 A TW105114781 A TW 105114781A TW 105114781 A TW105114781 A TW 105114781A TW 201713641 A TW201713641 A TW 201713641A
Authority
TW
Taiwan
Prior art keywords
methyl
indol
amine
quinoxaline
pyridin
Prior art date
Application number
TW105114781A
Other languages
English (en)
Chinese (zh)
Inventor
查爾斯 亨利 羅柏特 費斯 法柏瑞杜斯
馬特斯 歐泰彎 諾瓦克
卡泰辛納 安娜 威克利克
亞麗克山卓拉 芭芭拉 沙賓納茲
馬辛 多明尼克 比恩
安娜 瑪歌札達 布達
帕瓦 斯賽潘 古齊克
克茲拓夫 羅曼 賈古比克
莫尼卡 馬西賽克
卡泰辛納 克威辛卡
馬特斯 麥克 湯辛克
麥克 米寇拉杰 高爾索斯基
安德杰 崗德拉
路卡茲 皮歐特 杜德克
Original Assignee
賽爾維他股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽爾維他股份公司 filed Critical 賽爾維他股份公司
Publication of TW201713641A publication Critical patent/TW201713641A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105114781A 2015-05-13 2016-05-12 經取代之喹喏啉衍生物 TW201713641A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001451 2015-05-13
EP15460017 2015-05-14

Publications (1)

Publication Number Publication Date
TW201713641A true TW201713641A (zh) 2017-04-16

Family

ID=56081443

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105114781A TW201713641A (zh) 2015-05-13 2016-05-12 經取代之喹喏啉衍生物

Country Status (9)

Country Link
US (1) US20180148429A1 (enExample)
EP (1) EP3294729A1 (enExample)
JP (1) JP2018515612A (enExample)
CN (1) CN107635986A (enExample)
AU (1) AU2016261031A1 (enExample)
CA (1) CA2979302A1 (enExample)
IL (1) IL254870A0 (enExample)
TW (1) TW201713641A (enExample)
WO (1) WO2016180536A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2823180T3 (es) * 2016-07-14 2021-05-06 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos con heteroarilo
EP3538518A1 (en) * 2016-11-08 2019-09-18 Merck Patent GmbH Substituted quinoxaline derivatives as inhibitors of pfkfb
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
US20200275661A1 (en) * 2017-09-26 2020-09-03 Nippon Soda Co., Ltd. Quinoline compound, and agricultural and horticultural fungicide
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
DK3768684T3 (da) 2018-03-22 2023-04-24 Hoffmann La Roche Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
JP2022508751A (ja) * 2018-10-15 2022-01-19 ゲロ ディスカバリー リミテッド ライアビリティ カンパニー Pfkfb3阻害剤とその使用
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
CN114072405A (zh) 2019-07-03 2022-02-18 豪夫迈·罗氏有限公司 杂环单酰基甘油脂肪酶(magl)抑制剂
KR20220034104A (ko) 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
CN121045142A (zh) * 2019-08-06 2025-12-02 北卡罗来纳查佩尔山大学 Rna靶向配体、其组合物以及其制备和使用方法
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
MX2022003023A (es) 2019-09-23 2022-04-07 Hoffmann La Roche Compuestos heterociclicos.
CN115515959B (zh) * 2020-05-08 2026-03-31 默克专利股份公司 用作tead结合剂的三环杂环
EP4185564A1 (en) * 2020-07-23 2023-05-31 Merck Patent GmbH Tricyclic heterocycles
WO2022043284A1 (en) 2020-08-26 2022-03-03 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as magl inhibitors
PE20231372A1 (es) 2020-09-03 2023-09-07 Hoffmann La Roche Compuestos heterociclicos
WO2022115521A1 (en) 2020-11-25 2022-06-02 Servier Pharmaceuticals, Llc (heteo)aryl substituted pyrrolo-, pyrazolo- and triazolopyridazine derivates as mat2a inhibitors
EP4337653A4 (en) * 2021-06-02 2025-07-23 Univ North Carolina Chapel Hill RNA TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME
WO2023247670A1 (en) 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors
WO2025084787A1 (ko) * 2023-10-17 2025-04-24 가천대학교 산학협력단 신규 퀴녹살린 화합물, 이의 제조방법 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US20140128392A1 (en) * 2009-03-19 2014-05-08 Bioenergenix Heterocyclic compounds for the inhibition of pask
US9403769B2 (en) * 2010-02-22 2016-08-02 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
TW201311149A (zh) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
WO2013148228A1 (en) * 2012-03-29 2013-10-03 Advanced Cancer Therapeutics, Llc Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic

Also Published As

Publication number Publication date
JP2018515612A (ja) 2018-06-14
CA2979302A1 (en) 2016-11-17
WO2016180536A1 (en) 2016-11-17
AU2016261031A1 (en) 2017-10-05
EP3294729A1 (en) 2018-03-21
US20180148429A1 (en) 2018-05-31
CN107635986A (zh) 2018-01-26
IL254870A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
TWI923663B (zh) 吲唑化合物
AU2020204241B2 (en) Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
TWI921912B (zh) Fgfr抑制劑及其使用方法
CN107635986A (zh) 取代的喹喔啉衍生物
US10851080B2 (en) Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds
US20250368641A1 (en) Quinoline compounds as inhibitors of kras
CN103874700B (zh) 吡唑并[3,4‑c]吡啶化合物和使用方法
JP6317360B2 (ja) 2−アミノピリジン化合物
US20160016951A1 (en) Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
CN107108561A (zh) 用作irak抑制剂的杂芳基化合物及其用途
CN101772500A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
EP3053923B1 (en) Triazolopyrazine derivatives as tyrosin kinase inhibitors
AU2012318874A1 (en) 1,3-substituted azetidine PDE10 inhibitors
KR20180021702A (ko) TBK/IKKε 억제제 화합물 및 이의 용도
JP7716777B2 (ja) 窒素含有多環式縮合環系化合物、その医薬組成物、製造方法及び用途
TW201710250A (zh) 經取代之喹喏啉衍生物
WO2021233236A1 (zh) 取代的杂芳基化合物及其组合物和用途
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
JP2025514670A (ja) HPK1阻害剤としてのピリド[3,2-d]ピリミジン
JP7284161B2 (ja) ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用
WO2025113625A1 (zh) 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用
HK40070481A (en) Fgfr inhibitors and methods of use thereof
HK40070481B (en) Fgfr inhibitors and methods of use thereof
HK1193807B (en) Pyrazolo[3,4-c]pyridine compounds and methods of use
HK1193807A (en) Pyrazolo[3,4-c]pyridine compounds and methods of use